Table 2.

Associations between CN expression, clinical parameters and disease-free survival

Clinical parameters	Disease-free survival (months)
	Total type				Clear-cell carcinoma				Serous carcinoma				Papillary serous cystadenocarcinoma
	N	Mean	95% CI	p-value	N	Mean	95% CI	p-value	N	Mean	95% CI	p-value	N	Mean	95% CI	p-value
CN expression
≦50	24	97.67	73.67, 121.66	0.41	7	77.70	60.20, 95.20	0.27	7	143.33	92.76, 191.53	0.43	10	62.80	42.71, 82.89	0.89
>50	17	87.15	72.12, 102.19		10	56.29	26.30, 86.27		2	116.39	95.55, 160.14		5	64.60	46.88, 82.32
Age (years)
<50	26	181.38	157.41, 205.34	< 0.01*	10	83.33	69.17, 97.50	0.07	7	188.30	163.97, 212.63	0.04*	9	66.71	46.30, 87.12	0.50
≧50	24	82.12	59.05, 105.19		9	51.60	26.31, 76.87		8	98.49	77.65, 142.24		7	57.33	36.48, 78.19
Pathological stage
I~II	29	167.83	141.87, 193.79	0.09	9	76.78	57.89, 95.67	0.52	10	168.30	123.97, 212.63	0.99	10	73.40	60.50, 86.30	0.04*
III~IV	20	68.24	48.96, 87.52		9	64.22	39.29, 89.16		5	86.80	56.65, 116.95		6	40.17	14.87, 65.46
Tumor size (mm3)
< 395	26	132.37	97.50, 167.24	0.19	5	75.60	59.41, 91.78	0.06	12	154.33	103.76, 202.53	0.36	9	65.29	43.36, 87.21	0.08
≧395	24	86.30	72.20, 100.40		14	42.40	7.14, 77.66		3	96.39	75.55, 140.14		7	58.44	38.35, 78.54
LN metastasis
No	31	163.70	137.35, 190.06	0.08	11	72.64	54.13, 91.15	0.55	10	168.30	123.97, 212.63	0.99	10	73.40	60.50, 86.30	0.04*
Yes	19	65.44	45.02, 85.86		8	58.75	29.89, 87.61		5	86.80	56.65, 116.95		6	40.17	14.87, 65.46
Distant metastasis
No	48	153.55	130.07, 177.03	0.02*	18	69.19	52.48, 85.89	0.17	15	167.80	131.11, 204.49	─	15	64.20	49.30, 79.10	0.15
Yes	2	21.00	19.04, 22.96		1	22.00	22.00, 22.00		0	─	─		1	20.00	20.00, 20.00
Ascites
No	26	153.63	121.72, 185.54	0.63	10	66.00	43.09, 88.91	0.98	11	164.33	113.76, 212.53	0.27	5	77.80	66.93, 88.67	0.29
Yes	24	75.63	59.23, 92.02		9	67.44	44.19, 90.70		4	97.49	76.65, 141.24		11	54.00	34.39, 73.61
Chemotherapeutic response
No	2	51.00	0, 105.05	0.60	1	82.00	82.00, 82.00	0.48	0	─	─	─	1	20.00	20.00, 20.00	0.07
Yes	37	95.81	77.57, 114.05		15	64.06	41.89, 86.23		10	102.80	70.29, 135.31		12	65.25	49.35, 81.15
Chemotherapeutic resistance
No	21	126.95	109.94, 143.96	< 0.01*	5	73.20	50.76, 95.64	0.12	5	141.30	70.29, 212.31	0.02*	11	75.09	63.04, 87.15	< 0.01*
Yes	11	31.95	16.56, 47.33		5	32.60	8.37, 56.83		1	32.00	32.00, 32.00		5	30.20	8.41, 51.99
CA125 (U/ml)
< 324	24	133.50	97.04, 169.96	0.18	11	78.46	62.08, 94.83	0.27	5	162.44	111.65, 213.24	0.85	8	71.13	54.12, 88.13	0.28
≧324	24	88.03	75.20, 100.86		7	56.00	26.65, 85.35		9	90.20	66.01, 114.39		8	51.75	29.15, 74.35
CA19–9 (U/ml)
< 21.55	24	147.26	112.14, 182.39	0.86	8	71.38	47.59, 95.16	0.71	8	153.29	93.79, 212.78	0.51	8	55.38	35.44, 75.31	0.55
≧21.55	23	105.67	84.02, 127.31		7	66.06	42.89, 89.23		7	124.50	96.08, 152.92		7	64.00	40.54, 87.46
CA72–4 (U/ml)
< 7.89	25	174.20	147.38, 201.03	0.04*	8	80.00	59.83, 100.17	0.21	9	164.33	115.76, 212.91	0.80	8	74.75	59.62, 89.88	0.05*
≧7.89	24	69.33	52.59, 86.08		10	60.74	38.11, 83.37		6	89.67	64.02, 115.31		8	47.25	25.78, 76.36
AFP (ng/mL)
< 2.9	25	148.04	113.12, 182.97	0.82	7	79.00	66.73, 91.27	0.31	6	183.33	145.14, 221.52	0.30	12	65.25	49.35, 81.15	0.49
≧2.9	24	105.84	86.19, 125.49		11	61.10	37.54, 84.64		9	99.83	57.55, 142.12		4	50.00	16.57, 83. 44
CEA (ng/mL)
< 1.48	24	180.33	155.28, 205.39	0.03*	10	81.49	69.17, 97.50	0.02*	8	177.14	128.41, 225.88	0.67	6	58.67	37.69, 79.65	0.39
≧1.48	24	89.07	66.13, 112.02		8	31.60	16.31, 56.87		7	109.38	76.09, 142.66		9	68.44	49.41, 87.48

Kaplan-Meier test using log rank; LN, lymph node; CA125, cancer antigen 125; CA19–9, cancer antigen 19–9; CA72–4, cancer antigen 72–4; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; *p < 0.05